EXELのニュース
Farallon steps up activism at biotech company Exelixis. Heres what could happen next 2023/04/15 11:26:07 CNBC
Farallon isnt an activist investor, but it wont shy away from a battle if necessary.
Farallon steps up activism at biotech company Exelixis. Here’s what could happen next 2023/04/15 11:26:00 CNBC
Farallon isn’t an activist investor, but it won’t shy away from a battle if necessary.
Exelexis supports two of Farallon''s board nominees as it faces proxy fight 2023/04/13 21:16:58 Seeking Alpha
Exelixis (EXEL) supports two of investor Farallon''s board nominees even as the investor last week said it planned to pursue a proxy fight with the biotech firm.Exelixis (EXEL) said…
Head and Neck Cancer Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies - Merck KGaA, Adlai Nortye Biopharma, HoffmannLa Roche, Exelixis, Immutep, Takeda, Amgen 2023/04/13 10:57:32 OpenPR
DelveInsight''s "Head and Neck Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Head and Neck Cancer, historical and forecasted epidemiology as well as the Head and Neck Cancer market trends in the United States,
Morgan Stanley maintains Exelixis at Equalweight 2023/04/12 15:03:37 Investing.com
https://www.investing.com/news/pro/exelixis-inc-receives-investment-bank-analyst-rating-update-3053806
Exelixis Inc.: Cancer Crusader With A Bright Future 2023/02/28 08:10:08 Seeking Alpha
Exelixis deals in the development and commercialization of cancer-related treatments and drugs. Read why I consider EXEL stock as a Buy now.
Mid-Day Stocks in Focus: Exelixis, Inc. (NASDAQ:EXEL), TEGNA Inc. (NYSE:TGNA) 2023/02/22 17:57:07 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Mid-Day Stocks in Focus: Exelixis, Inc. (NASDAQ:EXEL), TEGNA Inc. (NYSE:TGNA) appeared first on Stocks Equity .
Current Stocks’s Buzzers: Exelixis, Inc. (NASDAQ:EXEL -0.23%), Kinross Gold Corporation (NYSE:KGC -0.52%) 2023/02/21 16:22:30 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Current Stocks’s Buzzers: Exelixis, Inc. (NASDAQ:EXEL -0.23%), Kinross Gold Corporation (NYSE:KGC -0.52%) appeared first on Stocks Equity .
Bristol Myers Opdivo, Exelixis/Ipsen''s Cabometyx combo shows survival benefit in kidney cancer in 3 year data 2023/02/14 10:59:48 Seeking Alpha
Three year data from a phase 3 trial showed sustained survival and response rate benefits with Bristol Myers Squibb''s (BMY) Opdivo and Exelixis and Ipsen''s (IPSEY) (IPSEF)…
Opdivo (nivolumab) in Combination with CABOMETYX (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma 2023/02/13 22:00:00 Wallstreet:Online
Bristol Myers Squibb (NYSE: BMY) and Exelixis, Inc. (NASDAQ: EXEL) today announced three-year (36.5 months minimum; 44.0 months median) follow-up results from the Phase 3 CheckMate -9ER trial, demonstrating sustained survival and response rate benefits with the combination of Opdivo (nivolumab) and CABOMETYX (cabozantinib) versus sunitinib in the first-line treatment of advanced renal cell carcinoma
Exelixis, Inc. (EXEL) Q4 2022 Earnings Call Transcript 2023/02/08 01:48:03 Seeking Alpha
Exelixis, Inc. (NASDAQ:NASDAQ:EXEL) Q4 2022 Results Conference Call February 7, 2023 5:00 PM ETCompany ParticipantsSusan Hubbard - EVP, Public Affairs and IRMike Morrissey - President and…
Exelixis: Q4 Earnings Snapshot 2023/02/07 21:59:03 WTOP
ALAMEDA, Calif. (AP) — ALAMEDA, Calif. (AP) — Exelixis Inc. (EXEL) on Tuesday reported a fourth-quarter loss of $30.2 million,…
Exelixis Tops Q4 EPS by 8c By Investing.com 2023/02/07 21:34:06 Investing.com
Exelixis Tops Q4 EPS by 8c
Exelixis Non-GAAP EPS of -$0.03 beats by $0.02, revenue of $423.92M beats by $5.21M (NASDAQ:EXEL) 2023/02/07 21:10:47 Seeking Alpha
Exelixis press release (EXEL): Q4 Non-GAAP EPS of -$0.03 beats by $0.02.Revenue of $423.92M (-6.0% Y/Y) beats by $5.21M.Cabozantinib franchise achieved $1.40 billion in U.S. Net…
Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update 2023/02/07 21:05:00 Exelixis
- Total Revenues of $423.9 million for the Fourth Quarter of 2022, $1.61 billion for the Full Year 2022 - - Cabozantinib franchise achieved $1.40 billion in U.S. Net Product Revenues for the Full Year 2022, including $377.4 million for the Fourth Quarter 2022 - - GAAP Diluted EPS of $(0.09) for the